Autobio Diagnostics Co., Ltd. (603658.SS)
CNY 44.66
(-3.17%)
CNY 44.66
(-3.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.87 Billion CNY | -7.84% |
| 2022 | 1.77 Billion CNY | 21.15% |
| 2021 | 1.49 Billion CNY | 23.53% |
| 2020 | 1.19 Billion CNY | 5.29% |
| 2019 | 1.13 Billion CNY | 37.64% |
| 2018 | 832.06 Million CNY | 30.32% |
| 2017 | 640.85 Million CNY | 31.47% |
| 2016 | 487.74 Million CNY | 29.37% |
| 2015 | 375.13 Million CNY | 40.98% |
| 2014 | 263.36 Million CNY | 70.12% |
| 2013 | 154.03 Million CNY | 32.27% |
| 2012 | 117.67 Million CNY | 55.62% |
| 2011 | 75.32 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 372.41 Million CNY | -18.51% |
| 2024 Q1 | 363.85 Million CNY | 1.78% |
| 2024 Q2 | 415.22 Million CNY | -7.52% |
| 2023 Q3 | 415.5 Million CNY | 19.78% |
| 2023 Q4 | 428.9 Million CNY | 3.23% |
| 2023 Q1 | 305.89 Million CNY | -1.46% |
| 2023 FY | - CNY | -7.84% |
| 2023 Q2 | 346.87 Million CNY | 13.4% |
| 2022 Q4 | 310.44 Million CNY | -26.8% |
| 2022 Q3 | 424.09 Million CNY | 21.74% |
| 2022 Q1 | 290.55 Million CNY | 5.55% |
| 2022 FY | - CNY | 21.15% |
| 2022 Q2 | 348.35 Million CNY | 19.89% |
| 2021 Q3 | 350.26 Million CNY | 28.8% |
| 2021 FY | - CNY | 23.53% |
| 2021 Q1 | 196.11 Million CNY | -27.63% |
| 2021 Q2 | 271.93 Million CNY | 38.66% |
| 2021 Q4 | 275.28 Million CNY | -21.41% |
| 2020 Q3 | 302.08 Million CNY | 37.51% |
| 2020 FY | - CNY | 5.29% |
| 2020 Q1 | 112.49 Million CNY | -58.69% |
| 2020 Q2 | 219.68 Million CNY | 95.28% |
| 2020 Q4 | 270.98 Million CNY | -10.3% |
| 2019 Q3 | 270.25 Million CNY | 10.93% |
| 2019 Q2 | 243.62 Million CNY | 71.24% |
| 2019 FY | - CNY | 37.64% |
| 2019 Q4 | 272.28 Million CNY | 0.75% |
| 2019 Q1 | 142.26 Million CNY | -22.29% |
| 2018 Q3 | 191.39 Million CNY | 4.88% |
| 2018 Q4 | 183.08 Million CNY | -4.34% |
| 2018 FY | - CNY | 30.32% |
| 2018 Q1 | 110.71 Million CNY | -31.26% |
| 2018 Q2 | 182.47 Million CNY | 64.81% |
| 2017 Q3 | 155.25 Million CNY | 1.12% |
| 2017 FY | - CNY | 31.47% |
| 2017 Q4 | 161.06 Million CNY | 3.74% |
| 2017 Q1 | 66.63 Million CNY | -46.18% |
| 2017 Q2 | 153.54 Million CNY | 130.42% |
| 2016 Q1 | 57.89 Million CNY | -44.71% |
| 2016 Q3 | 123.28 Million CNY | 7.13% |
| 2016 Q4 | 123.8 Million CNY | 0.42% |
| 2016 Q2 | 115.07 Million CNY | 98.75% |
| 2016 FY | - CNY | 29.37% |
| 2015 Q1 | 71.43 Million CNY | 0.0% |
| 2015 Q3 | 99.04 Million CNY | 38.64% |
| 2015 Q4 | 104.72 Million CNY | 5.74% |
| 2015 FY | - CNY | 40.98% |
| 2015 Q2 | 71.43 Million CNY | 0.0% |
| 2014 FY | - CNY | 70.12% |
| 2013 FY | - CNY | 32.27% |
| 2012 FY | - CNY | 55.62% |
| 2011 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 1.11 Billion CNY | -68.156% |
| Joinn Laboratories(China)Co.,Ltd. | 639.51 Million CNY | -192.839% |
| WuXi AppTec Co., Ltd. | 14.16 Billion CNY | 86.783% |
| Thalys Medical Technology Group Inc. | -23.79 Million CNY | 7970.9% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 1.33 Billion CNY | -40.631% |
| Chemclin Diagnostics Co., Ltd. | 219.33 Million CNY | -753.815% |